Arjun V Balar1, Matthew D Galsky2, Jonathan E Rosenberg3, Thomas Powles4, Daniel P Petrylak5, Joaquim Bellmunt6, Yohann Loriot7, Andrea Necchi8, Jean Hoffman-Censits9, Jose Luis Perez-Gracia10, Nancy A Dawson11, Michiel S van der Heijden12, Robert Dreicer13, Sandy Srinivas14, Margitta M Retz15, Richard W Joseph16, Alexandra Drakaki17, Ulka N Vaishampayan18, Srikala S Sridhar19, David I Quinn20, Ignacio Durán21, David R Shaffer22, Bernhard J Eigl23, Petros D Grivas24, Evan Y Yu25, Shi Li26, Edward E Kadel26, Zachary Boyd26, Richard Bourgon26, Priti S Hegde26, Sanjeev Mariathasan26, AnnChristine Thåström26, Oyewale O Abidoye26, Gregg D Fine26, Dean F Bajorin3. 1. Genitourinary Cancers Program, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA. Electronic address: arjun.balar@nyumc.org. 2. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Barts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK. 5. Smilow Cancer Center, Yale University, New Haven, CT, USA. 6. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 7. Département de médecine oncologique, Université Paris-Saclay and Gustave Roussy, Villejuif, France. 8. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 9. Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA. 10. Department of Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain. 11. Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA. 12. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands. 13. Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA. 14. Division of Oncology/Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 15. Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. 16. Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA. 17. Department of Medicine, Division of Hematology and Oncology and Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 18. Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 19. Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada. 20. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. 21. Department of Medical Oncology, Hospital Universitario Virgen del Rocío and Institute of Biomedicine of Seville, Seville, Spain. 22. New York Oncology Hematology, Albany, NY, USA. 23. British Columbia Cancer Agency, British Columbia, Vancouver, Canada. 24. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 25. Division of Oncology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 26. Genentech, South San Francisco, CA, USA.
Abstract
BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. FINDINGS: Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. INTERPRETATION: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. FUNDING: F Hoffmann-La Roche, Genentech.
BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. FINDINGS: Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. INTERPRETATION:Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. FUNDING: F Hoffmann-La Roche, Genentech.
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544
Authors: Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz Journal: Nature Date: 2013-06-16 Impact factor: 49.962
Authors: M De Santis; P J Wiechno; J Bellmunt; C Lucas; W-C Su; L Albiges; C-C Lin; E Senkus-Konefka; A Flechon; L Mourey; A Necchi; W C Loidl; M M Retz; N Vaissière; S Culine Journal: Ann Oncol Date: 2015-12-16 Impact factor: 32.976
Authors: Yuji Sato; Jennifer K Bolzenius; Abdallah M Eteleeb; Xinming Su; Christopher A Maher; Jennifer K Sehn; Vivek K Arora Journal: JCI Insight Date: 2018-12-06
Authors: Henning Reis; Rene Serrette; Jennifer Posada; Vincent Lu; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Gopa Iyer; Samuel A Funt; Min Yuen Teo; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie Journal: Am J Surg Pathol Date: 2019-07 Impact factor: 6.394
Authors: Sarah Abou Alaiwi; Amin H Nassar; Wanling Xie; Ziad Bakouny; Jacob E Berchuck; David A Braun; Sylvan C Baca; Pier Vitale Nuzzo; Ronan Flippot; Tarek H Mouhieddine; Liam F Spurr; Yvonne Y Li; Taiwen Li; Abdallah Flaifel; John A Steinharter; Claire A Margolis; Natalie I Vokes; Heng Du; Sachet A Shukla; Andrew D Cherniack; Guru Sonpavde; Robert I Haddad; Mark M Awad; Marios Giannakis; F Stephen Hodi; X Shirley Liu; Sabina Signoretti; Cigall Kadoch; Matthew L Freedman; David J Kwiatkowski; Eliezer M Van Allen; Toni K Choueiri Journal: Cancer Immunol Res Date: 2020-04-22 Impact factor: 11.151
Authors: Maximilian Linxweiler; Fengshen Kuo; Nora Katabi; Mark Lee; Zaineb Nadeem; Martin G Dalin; Vladimir Makarov; Diego Chowell; Snjezana Dogan; Ian Ganly; A Ari Hakimi; Richard J Wong; Nadeem Riaz; Alan L Ho; Timothy A Chan; Luc G T Morris Journal: Clin Cancer Res Date: 2020-02-14 Impact factor: 12.531
Authors: Rimas V Lukas; Jordi Rodon; Kevin Becker; Eric T Wong; Kent Shih; Mehdi Touat; Marcella Fassò; Stuart Osborne; Luciana Molinero; Carol O'Hear; William Grossman; Joachim Baehring Journal: J Neurooncol Date: 2018-08-02 Impact factor: 4.130
Authors: Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan Journal: Oncoimmunology Date: 2018-03-15 Impact factor: 8.110